Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Author:

Khurshid Humera1,Ismaila Nofisat2ORCID,Bian Jessica3ORCID,Dabney Raetasha4,Das Millie5ORCID,Ellis Peter6ORCID,Feldman Jill7,Hann Christine8ORCID,Kulkarni Swati9,Laskin Janessa10ORCID,Manochakian Rami11ORCID,Mishra Deebya Raj12ORCID,Preeshagul Isabel13ORCID,Reddy Pavan14ORCID,Saxena Ashish15,Weinberg Frank16ORCID,Kalemkerian Gregory P.17ORCID

Affiliation:

1. Brown University, Providence, RI

2. American Society of Clinical Oncology (ASCO), Alexandria, VA

3. Maine Health, South Portland, ME

4. Texas Oncology, Grapevine, TX

5. Stanford University, Stanford, CA

6. Juravinski Cancer Center, Hamilton Health Sciences, Hamilton, Ontario, Canada

7. EGFR Resisters Patient Advocacy Group, Deerfield, IL

8. Johns Hopkins University, Baltimore, MD

9. Western University, Windsor Regional Cancer Program, Windsor, Ontario, Canada

10. University of British Columbia, Vancouver, British Columbia, Canada

11. Mayo Clinic, Jacksonville, FL

12. Janata Clinic, Aloknagar, Kathmandu, Nepal

13. Memorial Sloan Kettering Cancer Center, Montvale, NJ

14. Cancer Center of Kansas, Wichita, KS

15. Weill Cornell Medicine, New York, NY

16. University of Illinois, Chicago, IL

17. University of Michigan, Ann Arbor, MI

Abstract

PURPOSE To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. METHODS An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 95 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer. Additional information is available at www.asco.org/thoracic-cancer-guidelines .

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3